Ard van der Meij, country president of Novartis Group Austria, the nation’s leading pharmaceutical company, discusses the advantages in Austria for innovative companies and the steps required to bolster the generics and biosimilars market share within the Austrian market to create a sustainable healthcare ecosystem for the long-term. Furthermore, he provides an insight into the benefits of having three huge biologic production sites in western Austria and the critical importance of Novartis’s role in putting Austria on the pharmaceutical map.
What are the growth drivers in your current Novartis portfolio?
"As the leading company in Austria, we must leverage our influence to ensure that Austria can facilitate and embrace innovation as the healthcare environment here, as in other developed systems, is experiencing growing pressures."
